Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Spruce Biosciences reports phase IIa data on tildacerfont in classic congenital adrenal hyperplasia

May 26, 2021

Sparrow Pharmaceuticals presents new data on SPI-62 for Cushing's syndrome

May 26, 2021

Phase I data presented for MEDI-6570 in patients with T2DM

May 26, 2021

GR antagonist CORT-125329 shows selectivity and activity in vitro and in vivo

May 26, 2021

BBP-711 enters phase I healthy volunteer study

May 21, 2021

Phase Ib data for cagrilintide plus semaglutide in overweight or obese subjects

May 21, 2021

JD Bioscience presents 5-HT2A receptor antagonists

May 21, 2021

JCR initiates phase II trial of JR-142 in pediatric patients with growth hormone deficiency

May 19, 2021

Medshine Discovery discloses xanthine oxidase inhibitors

May 19, 2021

Australian researchers map out first genetic profile of skeletal master regulator cells

May 17, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...